Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Next Previous
Trial Profile

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filanesib (Primary) ; Carfilzomib
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms FACTOR
  • Sponsors Array BioPharma

    • Most Recent Events

    • 03 Feb 2015 According to Array Biopharma media release, the company is delaying the start of patient enrollment until the binimetinib and encorafenib transactions with Novartis are closed.
    • 08 Nov 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-001052-39)
    • 25 Mar 2014 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top